Johnson & Johnson
JNJ239.990USD
+2.200+0.93%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
577.46B시가총액
21.75P/E TTM
자세한 내용은 Johnson & Johnson 회사
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Johnson & Johnson 정보
종목 코드 JNJ
회사 이름Johnson & Johnson
상장일Oct 31, 2080
CEODuato (Joaquin Boix)
직원 수138100
유형Ordinary Share
회계 연도 종료Oct 31
주소One Johnson & Johnson Plaza
도시NEW BRUNSWICK
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호08933
전화17325242455
웹사이트https://www.jnj.com/
종목 코드 JNJ
상장일Oct 31, 2080
CEODuato (Joaquin Boix)
Johnson & Johnson의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+12015.00%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+3760.00%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
15.55K
+2695.00%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+2430.00%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
10.66K
--
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ms. Marillyn A. Hewson
Ms. Marillyn A. Hewson
Lead Independent Director
Lead Independent Director
3.00K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+12015.00%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+3760.00%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
15.55K
+2695.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Oncology-DARZALEX
3.67B
15.30%
Immunology-STELARA
1.57B
6.54%
Immunology-TREMFYA
1.42B
5.94%
Cardiovascular-ELECTROPHYSIOLOGY
1.42B
5.91%
Surgery-General
1.38B
5.74%
기타
14.53B
60.56%
지역별USD
이름
수익
비율
United States
13.71B
57.13%
Europe
5.44B
22.67%
Asia-Pacific, Africa
3.61B
15.06%
Western Hemisphere, excluding U.S.
1.23B
5.13%
사업별
지역별
사업별USD
이름
수익
비율
Oncology-DARZALEX
3.67B
15.30%
Immunology-STELARA
1.57B
6.54%
Immunology-TREMFYA
1.42B
5.94%
Cardiovascular-ELECTROPHYSIOLOGY
1.42B
5.91%
Surgery-General
1.38B
5.74%
기타
14.53B
60.56%
주식 보유 통계
마지막 업데이트: Mon, Nov 17
마지막 업데이트: Mon, Nov 17
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
10.10%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
기타
75.18%
주주
주주
비율
The Vanguard Group, Inc.
10.10%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
기타
75.18%
주주 유형
주주
비율
Investment Advisor
39.87%
Investment Advisor/Hedge Fund
24.21%
Research Firm
3.16%
Pension Fund
2.23%
Bank and Trust
2.07%
Insurance Company
1.61%
Sovereign Wealth Fund
1.41%
Hedge Fund
0.71%
Family Office
0.09%
기타
24.63%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
6009
1.82B
75.35%
+8.67M
2025Q3
5885
1.79B
74.44%
+16.50K
2025Q2
5920
1.78B
73.89%
-7.65M
2025Q1
6002
1.80B
74.62%
+4.60M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
235.57M
9.78%
-454.61K
-0.19%
Sep 30, 2025
State Street Investment Management (US)
132.21M
5.49%
-591.27K
-0.45%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
129.42M
5.37%
-343.10K
-0.26%
Sep 30, 2025
Geode Capital Management, L.L.C.
56.22M
2.33%
-4.39M
-7.25%
Sep 30, 2025
JP Morgan Asset Management
36.60M
1.52%
-110.36K
-0.30%
Sep 30, 2025
State Farm Insurance Companies
34.11M
1.42%
-262.64K
-0.76%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
31.93M
1.33%
+1.57M
+5.18%
Jun 30, 2025
Wellington Management Company, LLP
25.83M
1.07%
+956.24K
+3.84%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
25.26M
1.05%
-42.23K
-0.17%
Sep 30, 2025
BlackRock Asset Management Ireland Limited
20.93M
0.87%
+1.08M
+5.46%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares U.S. Pharmaceuticals ETF
23.7%
VanEck Pharmaceutical ETF
10.06%
FT Vest DJIA Dogs 10 Target Income ETF
9.82%
Health Care Select Sector SPDR Fund
9.32%
Proshares Ultra Health Care
9%
iShares U.S. Healthcare ETF
8.9%
JPMorgan Healthcare Leaders ETF
8.38%
First Trust NASDAQ Pharmaceuticals ETF
8.28%
Fidelity MSCI Health Care Index ETF
7.67%
Franklin Income Focus ETF
7.08%
더 보기
iShares U.S. Pharmaceuticals ETF
비율23.7%
VanEck Pharmaceutical ETF
비율10.06%
FT Vest DJIA Dogs 10 Target Income ETF
비율9.82%
Health Care Select Sector SPDR Fund
비율9.32%
Proshares Ultra Health Care
비율9%
iShares U.S. Healthcare ETF
비율8.9%
JPMorgan Healthcare Leaders ETF
비율8.38%
First Trust NASDAQ Pharmaceuticals ETF
비율8.28%
Fidelity MSCI Health Care Index ETF
비율7.67%
Franklin Income Focus ETF
비율7.08%
주식 배당금
지난 5년 동안 총
46.31B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Jan 02, 2026
JNJ.NB Final Cash Dividend of gross USD 1.3 paid on Mar 10, 2026 going ex on Feb 24, 2026
Feb 24, 2026
Mar 10, 2026
Feb 24, 2026
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
더 보기
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
